Jan. 3, 2025 /Mpelembe Media/ —  Oncolytics Biotech Inc.’s progress in developing cutting-edge immunotherapies for cancer treatment is the article’s main subject. The piece highlights several key advancements, including clinical trial results and collaborations with other companies. Financial information regarding Oncolytics is included, along with a disclaimer about the nature of the publication. Continue reading →